Khandan Keyomarsi
Affiliations: | 1994- | The University of Texas Graduate School of Biomedical Sciences at Houston |
Area:
Cell BiologyWebsite:
https://faculty.mdanderson.org/profiles/khandan_keyomarsi.htmlGoogle:
"Khandan Keyomarsi"Cross-listing: MPROTree
Parents
Sign in to add mentor| Richard G. Moran | grad student | 1989 | ||
| (Thesis:"Tumor cell responses to inhibition of thymidylate synthase") | ||||
Children
Sign in to add trainee
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Luo L, Yang P, Mastoraki S, et al. (2025) Single-cell RNA sequencing identifies molecular biomarkers predicting late progression to CDK4/6 inhibition in patients with HR+/HER2-Â metastatic breast cancer. Molecular Cancer. 24: 48 |
| Glaviano A, Singh SK, Lee EHC, et al. (2024) Cell cycle dysregulation in cancer. Pharmacological Reviews. 77: 100030 |
| Li M, Lulla AR, Wang Y, et al. (2024) Low Molecular Weight Cyclin E Confers a Vulnerability to PKMYT1 Inhibition in Triple-Negative Breast Cancer. Cancer Research |
| Lee H, Horbath A, Kondiparthi L, et al. (2024) Cell cycle arrest induces lipid droplet formation and confers ferroptosis resistance. Nature Communications. 15: 79 |
| Lulla AR, Akli S, Karakas C, et al. (2023) Neutrophil elastase remodels mammary tumors to facilitate lung metastasis. Molecular Cancer Therapeutics |
| Wingate HF, Keyomarsi K. (2023) Distinct Mechanisms of Resistance to CDK4/6 Inhibitors Require Specific Subsequent Treatment Strategies: One Size Does Not Fit All. Cancer Research. 83: 3165-3167 |
| Navarro-Yepes J, Kettner NM, Rao X, et al. (2023) Abemaciclib is effective in palbociclib-resistant hormone receptor-positive metastatic breast cancers. Cancer Research |
| DiPeri TP, Evans KW, Raso MG, et al. (2023) Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Haddad TC, Suman VJ, D'Assoro AB, et al. (2023) Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial. Jama Oncology |
| Nguyen TDT, Wang Y, Bui TN, et al. (2023) Sequential targeting of retinoblastoma and DNA synthesis pathways is a therapeutic strategy for sarcomas that can be monitored in real-time. Cancer Research |